Matinas BioPharma Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. (MTNB) is a U.S.-listed biopharmaceutical company traded on NYSE American, headquartered in Bedminster, New Jersey, United States. Founded in May 2013, the company was built around a clear thesis: improve the delivery of hard-to-formulate anti-infective therapies through its proprietary lipid nanocrystal (LNC) platform, also described in its materials as a cochleate/encochleated delivery approach. For French-speaking investors, this is a classic clinical-stage biotechnology story: high R&D intensity, limited current commercial visibility, and a valuation that depends heavily on clinical, regulatory, and financing milestones. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/annual-reports/content/0001493152-23-007726/0001493152-23-007726.pdf?utm_source=openai)) The company’s pipeline is currently centered on two lead programs. MAT2203 is Matinas’ flagship asset: an oral formulation of amphotericin B, a potent antifungal agent that is traditionally administered intravenously. The company is developing MAT2203 to potentially provide a safer, more convenient oral option for serious fungal infections, including invasive aspergillosis. MAT2501 is the second core program: an oral formulation of amikacin aimed at difficult bacterial infections, including nontuberculous mycobacteria (NTM) and other resistant pathogens. Matinas also positions its LNC platform as a broader enabling technology that could support future programs in inflammation and oncology. ([matinasbiopharma.com](https://www.matinasbiopharma.com/lnc-technology/mat2203?utm_source=openai)) From a competitive perspective, Matinas is not a commercial-stage pharmaceutical company with approved products and recurring sales. Instead, it seeks to differentiate itself through drug-delivery innovation in anti-infectives, with the goal of converting IV-only medicines into oral therapies that may reduce toxicity and improve patient convenience. That proposition is scientifically attractive, but execution remains the key risk: the company still depends on clinical data, regulatory interactions, and potential strategic partnerships to advance its pipeline. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/248/matinas-biopharmas-lead-antibacterial-development?utm_source=openai)) Recent developments matter materially for the equity story. In April 2026, Matinas disclosed that it had received a notice of non-compliance from NYSE American regarding continued listing standards, tied to stockholders’ equity and a history of losses. During 2025, the company focused mainly on board refreshment and governance changes, while continuing to highlight MAT2203 as its lead program. For investors, this creates a profile with meaningful scientific upside, but also elevated balance-sheet and listing-risk considerations. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/all-sec-filings/content/0001493152-26-015170/form8-k.htm?utm_source=openai))